Peptide knowledge, connected to its evidence.

At a glance

What is it—and why does it matter?

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Tirzepatide activates GIP and GLP-1 receptors and, depending on glucose level, increases insulin secretion and lowers glucagon. Tirzepatide is used to help with weight loss and blood sugar control. Do not use MOUNJARO if you have had a serious allergic reaction to tirzepatide or any ingredient in MOUNJARO.

Evidence behind this overview

[1][2][3][4]

Each sentence above is copied from a published claim presentation. The links open its evidence record.

ClassDual GIP/GLP-1 receptor agonist

Structure39 amino acids

StatusFDA-approved ingredient

Products in this profile2

The simple version

Think of Tirzepatide as the active molecule. The named products below are specific ways that molecule is formulated, approved, and used. [1]

Simple guide

Tirzepatide, in plain English

The main points from the published research. Each one links to the source it comes from.

What it is

A lab-made peptide medicine that copies two natural body signals involved in blood sugar and appetite.

Tirzepatide is a dual GIP and GLP-1 receptor agonist.
Research in people
Source for this finding
“Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist”
Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.

Status: FDA-approved ingredient
Approved use: Mounjaro and Zepbound share an ingredient but not a single indication or dosing record.

What the research looks like

Most published findings come from studies in people.

140 People 54%
18 Animals or lab 7%
101 Other or unclear 39%

Counts show where findings come from, not how strong they are. Animal and lab findings are counted together because study types have not been labelled for this profile yet.

What studies in people found

Of the 78 patients, 52 started tirzepatide and 26 started semaglutide.
Research in peopleStudied in: patients with obesity
Source for this finding
“A total of 78 patients were included (tirzepatide n = 52; semaglutide n = 26).”
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
The authors conclude the current evidence does not prove ethnic equivalence and needs confirmation in adequately powered, ethnicity-stratified trials.
Research in people
Source for this finding
“These exploratory, indirect findings do not establish ethnic equivalence and require confirmation in adequately powered, ethnicity-stratified trials.”
Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
At 1 year, persistence was higher with Zepbound (81.9%) than with Wegovy (70.7%).
Research in people
Source for this finding
“One-year persistence was highest for Zepbound (81.9%) and Wegovy (70.7%), and significantly lower for Saxenda (34.2%) (log-rank P < .001).”
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025.
Compared with other anti-obesity medicines, tirzepatide use was linked to lower carpal tunnel syndrome risk (HR 0.75; 95% CI 0.65-0.85).
Research in peopleStudied in: adults aged ≥ 18 years who are overweight or obese
Source for this finding
“In comparison with other anti-obesity medications, tirzepatide was associated with reduced risks of both CTS (HR 0.75; 95% CI 0.65-0.85) and CTS surgery (HR 0.64; 95% CI 0.44-0.94).”
pubmed-42572932
The study compared tirzepatide with injectable semaglutide for preventing major adverse liver outcomes in adults with overweight/obesity and type 2 diabetes.
Research in peopleStudied in: adults with overweight or obesity and type 2 diabetes
Source for this finding
“This study aimed to compare the effectiveness of tirzepatide versus injectable semaglutide in preventing major adverse liver outcomes (MALO) among adults with overweight or obesity and type 2 diabetes.”
Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.

What animal and lab studies suggest

Not proven in people. Results in animals or cells often do not hold up in humans.

In male db/db mice, a body-weight reduction assay of CHEMBL4297839 at 30 nmol/kg SC every 3 days for 60 days was run, but Activity was not reported.
Animal or lab studyStudied in: male db/db mouse model
Source for this finding
“Molecule: CHEMBL4297839 Target: Mus musculus (CHEMBL375) Assay: Hypoglycemic effect in male db/db mouse model assessed as reduction in body weight at 30 nmol/kg, sc administered every 3 days for 60 days and measured every 3 days Assay format: organism-based format Standard result: Activity not reported”
ChEMBL activities for CHEMBL4297839
In male db/db mice, an HbA1c reduction assay of CHEMBL4297839 at 30 nmol/kg SC every 3 days for 60 days was run, but Activity was not reported.
Animal or lab studyStudied in: male db/db mouse model
Source for this finding
“Molecule: CHEMBL4297839 Target: Mus musculus (CHEMBL375) Assay: Hypoglycemic effect in male db/db mouse model assessed as reduction in HbA1c level at 30 nmol/kg, sc administered every 3 days for 60 days and measured on day 18, 31, 37, 52, 58 and 60 by auto-chemistry analyzer Assay format: organism-based format Standard result: Activity not reported”
ChEMBL activities for CHEMBL4297839
In these mice, tirzepatide reduced food intake.
Animal or lab studyStudied in: male and female c57bl/6j mice fed a high fat diet for 8 weeks
Source for this finding
“Tirzepatide reduced body weight, food intake, and adiposity in both sexes”
Increased Energy Expenditure through Intermittent Cold Exposure Does Not Enhance Tirzepatide Induced Weight-loss in Obese Mice.

Safety

Boxed warning on the product label

Labels warn about thyroid C-cell tumors observed in rats; human relevance is unknown.

Serious risks listed on the product label:

Acute pancreatitis
Hypoglycemia with insulin or secretagogues
Acute kidney injury from dehydration

Do not use MOUNJARO if you or your family have had MTC, or if you have MEN 2.
Regulatory recordApplies to: patients with a personal or family history of mtc or men 2
Source for this finding
“MOUNJARO is contraindicated in patients with:A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)[see Warnings and Precautions (5.1)].”
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
Do not use MOUNJARO if you have had a serious allergic reaction to tirzepatide or any ingredient in MOUNJARO.
Regulatory recordApplies to: patients with known serious hypersensitivity to tirzepatide or excipients
Source for this finding
“Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.”
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
“Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.”
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
Using MOUNJARO with a sulfonylurea (or other insulin secretagogue) or insulin may increase hypoglycemia risk, including severe hypoglycemia.
Regulatory recordApplies to: patients receiving mounjaro in combination with an insulin secretagogue or insulin
Source for this finding
“Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia[see Adverse Reactions (6.1), Drug Interactions (7.1)].”
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022

Read the full label safety summary ↓

How it's used

These describe specific products as labelled or studied. They are not dosing instructions.

Mounjaro is given as a once-weekly under-the-skin injection using prefilled pens (abdomen, thigh, or upper arm).
Regulatory record
Source for this finding
“It is given by injection using prefilled pens. It is injected once a week, under the skin of the abdomen (belly), thigh, or upper arm”
Mounjaro | European Medicines Agency (EMA)
Tirzepatide is given as a subcutaneous injection once per week.
Regulatory record
Source for this finding
“Administer MOUNJARO once weekly, any time of day, with or without meals.Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.Rotate injection sites with each dose.”
These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO.MOUNJARO®(tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022

What we don't know

This profile does not list specific open questions yet.

A missing finding does not mean something is safe or effective.

Identity + structure

A molecule, not a product name.

Chemical identity and product identity are kept separate so evidence does not leak between formulations or indications.

Preferred name	Tirzepatide	Ingredient
Pharmacologic class	Dual GIP/GLP-1 receptor agonist	Profile record
Peptide structure	39 amino acids	Profile record
Also indexed as	tirzepatide · dual incretin agonist	Search aliases

Mechanism + clinical pharmacology

What it does in the body.

Primary explanation

Agonism at GIP and GLP-1 receptors increases glucose-dependent insulin secretion, reduces glucagon, slows gastric emptying, and reduces food intake. [1]

See all 298 findings and sourcesEvery finding, grouped by topic, with its exact source passages

Evidence ledger

What the evidence says.

259 profile findings. Contextual and unclassified research is listed separately below. Open each citation to inspect the source and its limitations.

These are evidence statements, not individualized medical instructions. Product, dose, population, and study context remain attached to each source.

Study findings

What studies observed in defined populations, comparators, and time periods.

89 statements

Source-backed statement

Compared with GLP-1 receptor agonists, tirzepatide was linked to lower acute myocardial infarction risk (HR 0.70 [95% CI, 0.53-0.93]).

Sources[49]

Sources[5]

Sources[5]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Over 3 years, tirzepatide was associated with lower predicted 10-year CVD risk than placebo in people with obesity/overweight and prediabetes.

Sources[64]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

At 12 months, people with recorded weights who started tirzepatide for obesity had a mean weight loss of -17.4% (95% CI: -17.5 to -17.3).

Sources[62]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Compared with controls, tirzepatide was associated with a lower HbA1c by 6.5 mmol/mol (95% CI 3.8-9.1; p < 0.001) (0.6% [0.4-0.8]).

Sources[37]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In these mice, tirzepatide reduced food intake.

Sources[95]

Sources[95]

Sources[80]

In male ICR mice, a 4-day body-weight assessment at 30 nmol/kg SC was performed for CHEMBL4297839, but Activity was not reported.

Sources[5]

Sources[55]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In this cohort of youth on tirzepatide, BMI went down by the first follow-up.

Sources[66]

Human research · design must be checked

1 cited source · Study independence not established

Sources[77]

Human research · design must be checked

1 cited source · Study independence not established

Sources[79]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

In CHO cells expressing human GLP-1R, CHEMBL4297839 acted as an agonist with EC50 0.77 nM (30-min cAMP assay).

Sources[5]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Sodium caprate (C10) was chosen as an absorption enhancer based on acid-neutralizing capacity, Caco-2 permeability enhancement, and preliminary rat PK screening.

Sources[54]

Animal / laboratory evidence

1 cited source · Study independence not established

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Tirzepatide lowers glucagon levels.

Sources[33]

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The baseline results came from the PERCEPTIONS survey, an observational, longitudinal real-world US study of adults starting tirzepatide for obesity management.

Sources[55]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Tirzepatide is a long-acting GIP receptor and GLP-1 receptor agonist.

Sources[39]

Human research · design must be checked

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

In CHO cells, CHEMBL4297839 activated the human GLP-1 receptor with an EC50 of 0.77 nM (cAMP assay, 30 minutes).

Sources[5]

The study measured vascular function with CAVI and body composition with SMI and BFI (InBody720).

Sources[35]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The study tracked time to first MALO (cirrhosis, decompensated events, hepatocellular carcinoma) in new users of tirzepatide vs semaglutide, using propensity score matching.

Sources[72]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

The study aimed to describe experiences and workplace outcomes in full-time employed US adults with obesity or overweight who were starting tirzepatide for obesity management, and to assess views on employer insurance coverage for obesity medicines.

Sources[55]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

Human evidence supports that tirzepatide-related weight reduction is largely driven by reduced appetite and energy intake.

Sources[79]

The study matched tirzepatide and GLP-1RA patients 1:1 using propensity scores based on demographics, comorbidities, and IBD medications.

Sources[93]

Human research · design must be checked

1 cited source · Study independence not established

Sources[14]

Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Safety findings

Observed or labeled risks, adverse effects, and safety signals.

6 statements

Source-backed statement

In rats, tirzepatide caused thyroid C-cell tumors in a way that depended on dose and how long it was given, at clinically relevant exposures.

Sources[9]

Animal / laboratory evidence

1 cited source · 1 regulatory record

Animal or laboratory findings do not establish benefit or safety in people.

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

Pancreatitis (including severe and sometimes fatal forms) has been seen with GLP-1 medicines or MOUNJARO; if pancreatitis is suspected, stop MOUNJARO and manage it.

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

Sources[6]

Regulatory record

1 cited source · 1 regulatory record

Sources[13]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Regulatory status

Product-, indication-, and jurisdiction-specific regulatory records.

1 statement

Source-backed statement

MOUNJARO is used to lower the risk of major heart-related events in high-risk adults with type 2 diabetes.

Sources[12]

Regulatory record

1 cited source · 1 regulatory record

Sources[10]

Regulatory record

1 cited source · 1 regulatory record

Sources[11]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Studied populations

Who was represented in a study, label, or registry record.

2 statements

Source-backed statement

No dose change is recommended for kidney impairment, and tirzepatide PK did not change in renal impairment (including ESRD).

Sources[8]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Source-backed statement

Mounjaro is used with diet and physical activity for type 2 diabetes in people aged 10 years and above when diabetes is not well controlled.

Sources[16]

Regulatory record

1 cited source · 1 regulatory record

Sources[70]

Sources[93]

Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Source-backed statement

MOUNJARO is tirzepatide, a once-weekly GIP and GLP-1 receptor agonist.

Sources[10]

Regulatory record

1 cited source · 1 regulatory record

How to read this evidence

1 cited passage across 1 source record.

Additional research & classification gaps

39 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.

Inspect contextual research (39)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The analysis checked whether Framingham-based predicted treatment effects matched observed cardiovascular events in the REWIND trial.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
The use of the FHS equation to predict treatment effect (model-derived hazard ratio, HR) was examined for consistency with the observed cardiovascular events in the REWIND trial.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Tirzepatide 15 mg ranked highest for reducing weight and waist size based on P-scores.

Research context only—not evidence of a treatment effect.

Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
Tirzepatide 15 mg ranked highest for weight and waist reduction across analyses based on P-scores.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Because the SUMMIT and EMPEROR-Preserved trials differed, a direct statistical comparison between tirzepatide and empagliflozin is not valid.

Research context only—not evidence of a treatment effect.

pubmed-42533465
Because SUMMIT and EMPEROR-Preserved differed in design and populations, direct comparison between agents is not statistically valid; each should be assessed on its own evidence base.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

From June 2024 to March 2025, monthly tirzepatide quantity rose from 392,354 to 1,027,955 kit units.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Complete monthly data were available from June 2024 through March 2025. During this interval, monthly quantity increased from 392,354 to 1,027,955 kit units;

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

At baseline, WPAI showed mean activity impairment of 43.0% and overall work impairment of 32.4%, mainly due to presenteeism.

Research context only—not evidence of a treatment effect.

pubmed-42518363
WPAI results indicated substantial impairment, with mean activity impairment of 43.0% and overall work impairment of 32.4%, driven primarily by presenteeism.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The primary outpatient total was 7,829,974.7 kit units.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The primary outpatient total was 7,829,974.7 kit units.

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Tirzepatide did not show consistent associations with changes in fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
No consistent associations were observed between tirzepatide and changes in fibrinogen, tissue plasminogen activator:Ag, or thrombomodulin.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

2 cited passages across 1 source record. 1 publication group(s) lack a resolved study identity.

From June 2024 to March 2025, outside-institution dispensing rose from 329,431 (84.0%) to 899,994 (87.6%) kit units.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
outside-institution quantity increased from 329,431 kit units (84.0%) to 899,994 kit units (87.6%);
Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
outside-institution quantity increased from 329,431 kit units (84.0%) to 899,994 kit units (87.6%);

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

By week 72, adiponectin increased more with tirzepatide than placebo at 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
adiponectin (21.1%, 35.1%, 47.7%)

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

By week 72, E-selectin decreased more with tirzepatide than placebo at 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
E-selectin (-12.6%, -20.0%, -26.4%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Monthly data were complete from June 2024 through March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
Complete monthly data were available from June 2024 through March 2025.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

A post hoc analysis evaluated whether tirzepatide’s effects on predicted CVD risk were durable for primary CVD prevention in obesity in the SURMOUNT-1 3-year study.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
This post hoc analysis assessed the durability of tirzepatide for primary cardiovascular disease (CVD) prevention in obesity, based on predicted CVD risk, in the SURMOUNT-1 (SM-1) 3-year study.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Other possible concerns, depending on context, include thiamine, folate, vitamin A, other fat-soluble vitamins, and potassium.

Research context only—not evidence of a treatment effect.

pubmed-42382663
with additional context-dependent concerns involving thiamine, folate, vitamin A, other fat-soluble vitamins and potassium.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The optimized process produced tablets with friability 0.58% and Carr’s index 24.

Research context only—not evidence of a treatment effect.

Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets.
yielded tablets with low friability (0.58%) and acceptable flowability (Carr's index, 24).

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

By week 72, hs-CRP decreased more with tirzepatide than placebo at 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
high-sensitivity C-reactive protein (-36.9%, -46.9%, -54.6%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

52.3% said they would consider switching jobs to get obesity-medicine coverage.

Research context only—not evidence of a treatment effect.

pubmed-42518363
52.3% reported that they would consider changing jobs in order to receive OM coverage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Of the absolute increase, 5 mg contributed 320,965 kit units (50.5%), and strengths ≥7.5 mg contributed 195,414 kit units (30.7%).

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The 5-mg product accounted for 320,965 kit units (50.5%) of the absolute increase, whereas strengths of 7.5 mg or higher collectively accounted for 195,414 kit units (30.7%).

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

Plasma biomarkers were measured at baseline, 24 weeks, and 72 weeks.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
collected at baseline, 24 weeks, and 72 weeks

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Among 518 full-time employees initiating tirzepatide, 81.7% said obesity medication coverage may increase job satisfaction.

Research context only—not evidence of a treatment effect.

pubmed-42518363
81.7% reported that OM coverage may increase job satisfaction

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Higher tirzepatide dosage was linked to greater weight loss.

Research context only—not evidence of a treatment effect.

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
In multivariable analyses, greater weight loss was independently associated with female sex, absence of type 2 diabetes, no prior obesity medication use, no concomitant weight gain-promoting medications, and higher tirzepatide dosage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The authors rated the certainty of evidence for tirzepatide as moderate-to-high.

Research context only—not evidence of a treatment effect.

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.
The certainty of evidence was moderate-to-high for GLP1RA, SGLT2i, Tirzepatide, DPP4i; low for metformin; low-to-moderate for other drugs.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Among 518 full-time employees initiating tirzepatide, 52.3% said they would consider changing jobs to receive obesity medication coverage.

Research context only—not evidence of a treatment effect.

pubmed-42518363
52.3% reported that they would consider changing jobs in order to receive OM coverage.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The main outcome measured was percent total body weight loss at 15 months, analyzed by sex and by age groups (≤ 45, 46-59, ≥ 60 years).

Research context only—not evidence of a treatment effect.

Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
Primary outcome was total body weight loss percentage (TBWL%) at 15 months, stratified by sex and age groups (≤ 45, 46-59, ≥ 60 years).

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Tirzepatide increases feelings of fullness.

Research context only—not evidence of a treatment effect.

Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation.
Tirzepatide is a dual receptor agonist that increases insulin levels, decreases glucagon levels, slows gastric emptying, and promotes feelings of fullness, contributing to significant weight loss.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Reported signals most often involve iron, vitamin B12, vitamin D, calcium, magnesium, and zinc across multiple nutrient-related domains.

Research context only—not evidence of a treatment effect.

pubmed-42382663
The most relevant signals involve hematologic, fat-soluble, bone-related, trace element, and electrolyte domains, particularly iron, vitamin B12, vitamin D, calcium, magnesium, zinc,

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

The main outcome was biomarker change at 72 weeks.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
with change at 72 weeks the primary outcome of interest

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Monthly quantity rose from 392,354 to 1,027,955 kit units from June 2024 to March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
During this interval, monthly quantity increased from 392,354 to 1,027,955 kit units;

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Among 518 full-time employees initiating tirzepatide, 96.5% believed employer-provided insurance should include obesity medication coverage.

Research context only—not evidence of a treatment effect.

pubmed-42518363
Majority (96.5%) believed employer-provided insurance should include OM coverage, citing improved health, productivity, and management of obesity-related complications.

Research context · scope unclassified

1 cited source · 1 linked study ID

How to read this evidence

1 cited passage across 1 source record.

By week 72, IL-6 decreased more with tirzepatide than placebo at 5, 10, and 15 mg.

Research context only—not evidence of a treatment effect.

Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis.
interleukin-6 (-25.4%, -27.8%, -30.2%)

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The 2.5 mg product increased in kit units (159,318 to 278,540) but its share fell (40.6% to 27.1%) from June 2024 to March 2025.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
The quantity of the 2.5-mg product increased from 159,318 kit units (40.6%) to 278,540 kit units (27.1%), while its share decreased.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

More prospective studies are needed to clarify how often micronutrient issues occur, how clinically important they are, and how to monitor them.

Research context only—not evidence of a treatment effect.

pubmed-42382663
while prospective studies are needed to define incidence, clinical relevance, and evidence-based monitoring strategies.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In Japan, tirzepatide is sold as Mounjaro in six strengths.

Research context only—not evidence of a treatment effect.

Outpatient Dispensing Patterns and Changes in Tirzepatide Strength Mix in Japan: A Study Using the National Open Claims Data.
marketed under the brand name Mounjaro, which is available in six strengths.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The analysis used cross-sectional survey data collected in Oct 2023–Apr 2024 and Oct 2024–Jan 2025.

Research context only—not evidence of a treatment effect.

pubmed-42491427
This secondary analysis utilized data from a cross-sectional survey of physicians and PwO from October 2023 to April 2024, and from October 2024 to January 2025.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The analysis used each drug as the other's comparator for RORs and PRRs.

Research context only—not evidence of a treatment effect.

Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
Disproportionality was evaluated using reporting odds ratios (RORs) and proportional reporting ratios (PRRs), utilizing each drug as the other's comparator.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The study calculated predicted 10-year CVD risk using the Framingham Heart Study equation.

Research context only—not evidence of a treatment effect.

Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.
Predicted 10-year CVD risk was calculated using the Framingham Heart Study (FHS) equation.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The study compared cardiovascular adverse-event signals for semaglutide vs tirzepatide in FAERS from January 2022 to March 2026.

Research context only—not evidence of a treatment effect.

Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
This study aimed to conduct a pharmacovigilance disproportionality analysis comparing cardiovascular adverse event (AE) signals between semaglutide and tirzepatide utilizing Food and Drug Administration Adverse Event Reporting System (FAERS) data from January 2022 to March 2026.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

The study used ROR, PRR, IC, and EBGM for disproportionality analysis.

Research context only—not evidence of a treatment effect.

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Disproportionality analysis used four algorithms (ROR, PRR, IC, EBGM).

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

These therapies may change diet, gut physiology, and weight-loss-related metabolism, raising concern for micronutrient disturbances with long-term use.

Research context only—not evidence of a treatment effect.

pubmed-42382663
These mechanisms may also modify dietary intake, gastrointestinal physiology, and weight-loss-related metabolic adaptations, raising concern about micronutrient disturbances during long-term treatment.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

With valid onset data, the median time to onset was 13 days, and 67.1% occurred within 30 days.

Research context only—not evidence of a treatment effect.

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database.
Among reports with valid onset data, median time to onset was 13 days, with 67.1% occurring within 30 days.

Safety + tolerability

Risks, organized for scanning.

A structured orientation to the label—not a complete prescribing-information substitute or an individual risk estimate.

Boxed warning

Labels warn about thyroid C-cell tumors observed in rats; human relevance is unknown. [1]

Contraindications

Personal or family history of medullary thyroid carcinoma
MEN 2
Serious hypersensitivity to tirzepatide

Common effects

Nausea
Diarrhea
Decreased appetite

Serious risks

Acute pancreatitis
Hypoglycemia with insulin or secretagogues
Acute kidney injury from dehydration

Structured from current product labeling [1]

Products + regulatory context

Same ingredient. Different records.

Brand names, routes, presentations, indications, and instructions are product-specific. This table is an index—not a substitution guide.

Product	Form	Profile scope	Record
Mounjaro	Weekly subcutaneous injection	Type 2 diabetes.	[1]
Zepbound	Weekly subcutaneous injection	Chronic weight management and product-specific obstructive sleep apnea use.	[7]

Do not infer dosing, interchangeability, or an approved use from the ingredient name alone. Open the current label for the exact product and presentation.

Administration, interactions + monitoring

The practical clinical context.

Administration boundary: Once-weekly subcutaneous product with label-directed escalation intended to improve tolerability. [1]

Research status + gaps

What still needs better answers.

A useful knowledge base names uncertainty as clearly as it names findings.

Some extracted findings are not shown because they did not pass Peplexicon's automated evidence checks.

How Peplexicon reads evidence

Authority: What kind of source is making the statement?
Independence: Do multiple citations represent separate studies—or the same evidence repeated?
Directness: Does the population, product, dose, outcome, and time horizon match the claim?
Consistency: Do credible sources support, qualify, or contradict one another?

References + discovery

Open the records yourself.

Authoritative records and published evidence are listed separately from live searches, which are discovery tools rather than pre-screened support.

1
Regulatory labelMounjaro prescribing information
Current DailyMed label for tirzepatide marketed as Mounjaro.
Open ↗
2
Literature indexEvery PubMed result for tirzepatide
Live National Library of Medicine literature search; results are not pre-screened or deduplicated.
Open ↗
3
Trial registryEvery registered study for tirzepatide
Live ClinicalTrials.gov search, including completed, active, and historical records.
Open ↗